Publications by authors named "E C Siegfried"
Background And Objectives: A wholesale recommendation against use of live virus vaccines in patients treated with any medication classified as an immunosuppressant has been based on global theoretical concerns rather than clinical outcomes for specific drugs.
Methods: A retrospective search of electronic medical records identified patients seen by the Allergy and/or Dermatology services between 2017 and 2023 at a pediatric tertiary center who received a live attenuated vaccine during the 6 week interval prior to the first prescription for methotrexate or dupilumab until 6 weeks after the last prescription for either medication. Individual charts of identified patients were manually reviewed for evidence of adverse events.
Article Synopsis
- The Measure Up 1, 2, and AD Up studies assessed the effectiveness and side effects of upadacitinib for treating atopic dermatitis in adolescents aged 12-17 over a period of 76 weeks, extending the research beyond the previously available 52-week data.
- In a randomized clinical trial, participants received either upadacitinib (15 mg or 30 mg) or a placebo, with some receiving topical corticosteroids, allowing for varied analysis of its efficacy and safety.
- Results showed that a significant percentage of adolescents achieved a major improvement in their condition, with 89.1%, 84.4%, and 87.8% meeting the criteria for reduction in severity, showcasing the medication
Article Synopsis
- * Mild-to-moderate AD is typically treated with topical anti-inflammatory medications and basic skin care, while moderate-to-severe cases often need systemic therapy, including off-label immunosuppressants, which carry safety concerns.
- * New targeted biologics and small molecules are emerging as more effective and safer treatment options for AD, leading to the development of standardized recommendations for treating pediatric patients with moderate-to-severe cases.
Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for transducing cytokine signals. The first JAKi was approved by the US Food and Drug Administration (FDA) in 2011 to treat rheumatoid arthritis in adults. A pediatric indication was not approved until 8 years later, for acute graft-versus-host disease.
View Article and Find Full Text PDF